LGG Registry Eligibility
Who can join the Low Grade Glioma Registry?
You are eligible to enroll in the Low Grade Glioma Registry if you:
Are currently aged 21-79 years, regardless of the age that you were diagnosed
Have ever been diagnosed with a grade 2 or 3 glioma OR a glioma that is IDH1/2 positive (IDH1/2+) regardless of grade
People who have had two or more surgeries for their glioma (separated by at least 6 months) are eligible to enroll in an additional study within the Registry called OPTIMUM.
Terms used to classify low grade glioma have changed over the last decade, and may include:
Oligodendroglioma
Astrocytoma
Oligo-Astrocytoma (or Mixed Glioma)
Low Grade Glioma
Glioma, not otherwise specified
IDH1/2+ Glioma
Glioblastoma, IDH1/2+
Study Eligibility for the Low Grade Glioma Registry
After you enroll in the Low Grade Glioma Registry, we will review your pathology report to confirm whether you are eligible for the study.
The Low Grade Glioma Registry places no restrictions on sex, gender, race, date of diagnosis, place of residence, or current glioma status.
What are Low Grade Glioma Registry participants asked to do?
*March 15, 2026: Please note that we will be transitioning our online consent and questionnaire from Hugo Health to REDCap. During this transition, please contact us at glioma@yale.edu if you would like to join the study.
Participation in the Low Grade Glioma Registry involves 3 steps:
-
First, we will ask you to share a copy of the pathology report from your glioma surgery to glioma@yale.edu to confirm your eligibility for the study. Then, you will need to sign a consent form.
-
Second, we ask you to complete an online questionnaire. The questionnaire takes about 30 minutes to complete, and asks for information about your glioma treatment and other aspects of your medical history.
-
Finally, the third part of the study asks you to provide a blood spot sample via mailed kit and give us permission to look at changes in your DNA. If you allow, we may also review your brain tissue specimens.
For additional details about participating in this study, download a copy of the Low Grade Glioma Registry consent form.
Study Eligibility for OPTIMUM for persons with recurrent Low Grade Glioma
After you enroll in the Low Grade Glioma Registry, we review your pathology report to confirm whether you are eligible for the OPTIMUM study.
A subset of persons in the Registry are eligible for OPTIMUM, i.e., such as those with low grade glioma that have had recurrence treated with a second surgery at least 6 months after the first surgery.
The OPTIMUM study places no restrictions on sex, gender, race, date of diagnosis, place of residence, or current glioma status.
However, OPTIMUM is currently limited to people who receive their care within the United States and Canada.
What are OPTIMUM participants asked to do?
*March 15, 2026: Please note that we will be transitioning our online consent and questionnaire from Hugo Health to REDCap. During this transition, please contact us at glioma@yale.edu if you would like to join the study.
Participation in OPTIMUM involves the same 3 steps as the Registry:
-
First, we will ask you to share a copy of the pathology reports from each of your glioma surgeries to glioma@yale.edu to confirm your eligibility for the study. Then, you will need to sign a consent form.
-
Second, we ask you to complete an online questionnaire. The questionnaire takes about 30 minutes to complete, and asks for information about your glioma treatment and other aspects of your medical history.
-
To examine inherited genes, we will ask you to provide one blood spot sample via mailed kit for whole exome and whole genome sequencing for this research.
To examine tumor genes, we will retrieve stored tissue specimens from all of your glioma surgeries.
Note that only excess tissue will be obtained from the pathology department. We will ask if you wish to have us share our findings from any of your genetic analyses with you and/or your healthcare provider.
Note: If you enroll in OPTIMUM you are automatically enrolled in the Low Grade Glioma Registry. No extra consent forms are required.
NEW: OPTIMUM participants are also eligible for clinical-level germline testing of 77 cancer genes via Ambry Genetics. Testing is free of charge. Participants who have a genetic change of clinical importance will receive one hour of telehealth genetic counseling and testing of blood relatives within 90 days of the participant test. Please contact us at glioma@yale.edu if interested.